decisionhealth Newsletters, Part B News - 2003 Issue 10 (October)
Medicare slashes cancer drug payments; lidocaine pay goes up
Subscribe or sign in to view the full article.
Article Overview
This article covers a Medicare drug payment update tied to the CMS single drug pricer policy. It is aimed at coding, billing, and reimbursement professionals who need to track changes in payment amounts for injectable and chemotherapy-related drugs, as well as newly payable items and notable market shifts mentioned in the update.
Why This Topic Matters
Payment changes in Medicare drug pricing can affect reimbursement, claims handling, and financial forecasting for practices and facilities that bill for administered drugs. The article is useful for readers monitoring quarterly pricing updates, carrier payment behavior, and the general impact of CMS drug payment policy.
What You Will Learn
- How a Medicare drug payment update is organized and reported
- Which drug payment categories saw the largest increases and decreases
- How newly payable drugs are introduced in the update
- How the article frames the impact of CMS pricing policy on billing and reimbursement
- What types of drugs were discussed in connection with oncology and other therapies
Who Should Read This
- Medical coders
- Billing specialists
- Reimbursement analysts
- Oncology practice staff
- Revenue cycle professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com